Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

Alfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, Elias Jabbour, Lynne V. Abruzzo, Srdan Verstovsek, Guillermo Garcia-Manero, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192). RESULTS: Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty-eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (P =.47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, P =.76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, P =.57) or complete cytogenetic response (77% vs 81%, P =.71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event-free survival (EFS) (88% vs 66%, P =.07) and OS (96% vs 82%; P =.08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second-line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS. CONCLUSIONS: Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs. Cancer

Original languageEnglish (US)
Pages (from-to)5085-5093
Number of pages9
JournalCancer
Volume117
Issue number22
DOIs
StatePublished - Nov 15 2011
Externally publishedYes

    Fingerprint

Keywords

  • BCR-ABL1
  • dasatinib
  • deletion
  • derivative chromosome 9
  • nilotinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quintás-Cardama, A., Kantarjian, H., Shan, J., Jabbour, E., Abruzzo, L. V., Verstovsek, S., Garcia-Manero, G., O'Brien, S., & Cortes, J. (2011). Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer, 117(22), 5085-5093. https://doi.org/10.1002/cncr.26147